The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed RRMM, with a median PFS of 13.3 vs 4.4 months and an ORR of 71% vs 42%. #mmsm | @cityofhope
#mmsm